Ex Vivo CMV Therapy Synklino offers a first-in-class ex vivo therapy (SYN002) administered during donor kidney perfusion to prevent CMV in transplant recipients, presenting a unique selling point for centers seeking targeted, reduced systemic exposure approaches.

Clinical Stage Advantage Phase 1 trial ongoing across four dose cohorts with CMV-positive donor recipients and defined leadership from a top transplant center, signaling near-term visibility for feasibility, safety and early efficacy data that can drive early-adopter interest.

Strategic Partnerships Collaborations with leading institutions (University of Cambridge, Addenbrooke’s Hospital) and a renowned transplant infectious diseases expert (Professor Atul Humar) bolster credibility for academic and clinical partnerships and co-development opportunities.

Funding Trajectory Significant Series A funding and ongoing financing rounds indicate strong investor interest and potential for accelerated manufacturing scale-up and clinical trial expansion, aligning with supplier and CRO collaboration opportunities.

Market Fit Signals The target market combines kidney transplant centers seeking improved CMV prevention with the potential for reduced systemic therapy burden, offering a compelling value proposition for hospitals prioritizing infection control and patient outcomes.